LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients

Gaziantep City Hospital34 enrolled

Overview

This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices. The study included 34 patients with end-stage heart failure who had either an HVAD or HeartMate 3 device and were followed for six months. The study assessed the relationship between LVAD index and selected routine biochemical markers related to hepatic and renal status, including ALT, AST, LDH, BUN, and creatinine. The study also evaluated whether LVAD index was associated with rehospitalization during follow-up.

This observational cohort study included adult patients with end-stage heart failure supported with continuous-flow left ventricular assist devices. Patients with HVAD and HeartMate 3 devices were followed during routine clinical visits over a six-month period. Device-estimated pump flow, power consumption, and LVAD index were recorded at follow-up visits. LVAD index was calculated as device-estimated pump flow divided by body surface area. Routine laboratory parameters, including ALT, AST, LDH, BUN, and creatinine, were evaluated as selected biochemical markers related to hepatic and renal status and tissue injury. Rehospitalization status during follow-up was also assessed. The study did not assign participants to any intervention and did not include protocol-driven pump speed adjustment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

End-stage Heart Failure Left Ventricular Assist Device Mechanical Circulatory Support

Interventions

HeartWare Ventricular Assist DeviceDEVICE

Patients in this group were supported with the HeartWare Ventricular Assist Device as part of routine clinical care. No device assignment or protocol-driven intervention was performed by the study investigators.

HeartMate 3 Left Ventricular Assist DeviceDEVICE

Patients in this group were supported with the HeartMate 3 left ventricular assist device as part of routine clinical care. No device assignment or protocol-driven intervention was performed by the study investigators.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older * Diagnosis of end-stage heart failure * First-time continuous-flow left ventricular assist device implantation * Implanted with either an HVAD or HeartMate 3 left ventricular assist device * Minimum follow-up period of six months Exclusion Criteria: * Incomplete data * Declined participation * HeartMate II pump implantation * Significant aortic valve dysfunction, including moderate or severe aortic regurgitation or stenosis

Outcomes

Primary Outcomes

Association Between LVAD Index and Selected Biochemical Markers

The association between LVAD index and selected routine biochemical markers, including ALT, AST, LDH, BUN, and creatinine, was evaluated during six-month follow-up. LVAD index was calculated as device-estimated pump flow divided by body surface area.

Time frame: Six months